Entekor tablet, after an oral administration it may undergo ADME properties.
Brand : Entekor
Ingredients : Entecavir
Strength : 0.5mg
Manufactured : Aprazer
Package : 30 tablets
Entekor tablets should be taken on an empty stomach (partially 2 hours after a meal or two hours earlier to the next meal). The usual prescribed dosage of Entekor tablets;In compensated cirrhosis
In this condition, the prescribed dosage of Entekor is 0.5mg should be administered orally as a single dose for the chronic hepatitis B viral infected patients who have newly started with Entekor. In past hepatitis B viremia, since taking lamivudine therapy or known lamivudine or telbivudine resistant alteration; the advised dosage of Entekor tablets is 1mg should be administered orally as a single dose.
The safety and efficacy of Entekor in children with the age of <2 years has not been established. In nucleoside naïve patients: 2 years or older with >30kg: 0.5mg of Entekor should be recommended as single dose. In lamivudine resistant patients: 2 years and older with >30kg: 1mg (2 tablet of 0.5mg Entekor) of Entekor should be recommended as a single dose.In decompensated liver cirrhosis
In decompensated condition, the suggested dosage is 1mg of Entekor should be taken as once a day.In renal damaged patients
If creatinine clearance decreased, then the apparent oral clearance of Entekor is also decreased.
The dosage recommendation for the patients;
With creatinine clearance of less than 50ml/min,
Hemodialysis patients and
For Continuous ambulatory peritoneal dialysis patients (CAPD)
CrCl ≥50ml/min: 0.5mg of Entekor should be recommended; in lamivudine resistant or decompensated condition 1mg of Entekor is recommend.
In 30 to <50ml/min: 0.5mg of Entekor is taken for every 48 hours; in lamivudine resistant or decompensated condition 0.5mg of Entekor as single dose or 1mg of Entekor taken for every 48 hours. In 10 to <30ml/min: 0.5mg of Entekor should be given for every 72 hours; in lamivudine resistant or decompensated condition 1mg of Entekor is recommended for every 72 hours. <10ml/min: & hemodialysis or CAPD: 0.5mg of Entekor is recommended for every 7 days; in lamivudine resistant or decompensated condition 1mg of Entekor should be given for every 7 days. In hepatic impairment patients, dosage adjustment of Entekor should not be recommended.
The most common adverse reaction occurs during or after the treatment; Severe aggravation of hepatitis B infection, Lactic acidosis, Hepatomegaly with steatosis, The common side effects like, Dyspepsia, Alopecia, Rash, Elevation of transaminase, Headache, Fatigue, Anaphylactic reactions, Dizziness, Diarrhea, Nausea, Vomiting, Somnolence, Insomnia, Hepatic failure, Gastrointestinal hemorrhage, Hepatocellular carcinoma
Some precautions should be taken while starting therapy with EntekorIn severe acute aggravation of hepatitis B:
This adverse may occur after discontinuation of anti-hepatitis B therapy. In this condition patient should be monitored frequently with liver functions and other laboratory follow ups. Continue the anti-hepatitis B therapy, if required.In HBV/HIV-1 co infected patients
Entecavir has not assessed in HIV/HBV co infected patients who are not concurrently taking effective anti-retroviral therapy. Entekor 0.5mg tablet used for HBV infection in patients who are infected with HIV, produce resistant to HIV nucleoside reverse transcriptase inhibitors, not exist to treat. Entekor 0.5mg should not be suggested to HBV/HIV co infected patients, also not receiving HAART. To overcome this type of condition, patient should be examining with HIV antibody testing before the therapy.In lactic acidosis & hepatomegaly with steatosis
This condition may occur due to the combination of nucleoside analog with anti-retroviral agents, this may happen mostly in women. The major fatal cases of this condition are obesity and extended nucleoside exposure. Lactic acidosis frequently occurs in decompensated liver cirrhosis patients, the only way to reduce this adverse is discontinuing the treatment with Entekor 0.5mg.
Entekor 0.5mg is not a CYP 450 enzyme substrate, inhibitor or inducers.
Since Entekor 0.5mg is majorly eliminated through kidneys, co administration of Entekor tablets with drugs which reduce the renal functions causes increasing the serum concentration of Entecavir and other combined drugs leads to adverse effects of Entekor.
Drug interaction may occur during combination of Entekor 0.5mg with the drugs which metabolized, inhibit or induce by CYP450 enzyme may have chance to alter pharmacokinetic properties of Entecavir. Co administration of Entekor 0.5mg with lamivudine, Adefovir or tenofovir disoproxil fumarate not expels any drug interaction.